The AdjuTec Pharma's projects have attracted €10mill in private investments and public grants to support R&D activities. The funding has taken our lead compound APC148 successfully through initial preclinical development and completion of our First-in-Human safety study.

AdjuTec Pharma will grow company value by funding early-stage clinical programs of pipeline projects. We will then partner with global companies to fund late-stage R&D, commercialisation and market penetration.

AdjuTec Pharma is entering a large, growing global market with an urgent and unmet medical need. The global β-lactam and β-lactamase inhibitors market size was €22 billion in 2018, and is projected to reach €28 billion by 2028, growing at a growth rate of 2.3% from 2019 to 2028 [1]. 10% of hospital patients and 30% of intensive-care-unit patients will contract a bacterial infection in hospitals, making healthcare-associated infections (HAIs) a key focus of our technology.

The global marketplace for HAIs caused by Gram-negative bacteria across the seven major pharmaceutical markets (US, EU4, UK and Japan) is projected to exceed €3 billion in sales by 2026, at a growth rate of 10.8% from 2016–2026, [2] representing huge opportunities for our APC148 technology.